Satellos Bioscience Inc., a regenerative medicine company that spun out of Stem Cell Network, recently announced that it has closed $55 million financing to support the development of its lead drug candidate for Duchenne muscular dystrophy with the potential to significantly change the prospects for improved quality of life for patients.
Satellos presented at the OBIO® Investment Summit and is a CAAP® alumnus.